Cadefrecitinib
Cadefrecitinib is an investigational new drug that is being developed by Lakefront Biotherapeutics for the treatment of dermatomyositis and systemic lupus erythematosus.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cadefrecitinib is an investigational new drug that is being developed by Lakefront Biotherapeutics for the treatment of dermatomyositis and systemic lupus erythematosus. It is a TYK2 kinase inhibitor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365630238 under CC BY-SA 4.0; modifications have been made.